Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight

Giuseppe Aprile, Elena Ongaro, Marzia Del Re, Stefania Eufemia Lutrino, Marta Bonotto, Laura Ferrari, Karim Rihawi, Giovanni Gerardo Cardellino, Nicoletta Pella, Romano Danesi, Gianpiero Fasola

Research output: Contribution to journalArticlepeer-review


Advanced gastric cancer ranks second as the global leading cause of cancer-related death and improvements in systemic chemotherapy have reached a plateau. Advanced molecular sequencing techniques help identifying patients more likely to respond to targeted agents; nevertheless we are still far from major breakthroughs. Although antiangiogenic drugs have produced notable advances, redundant pathways or mechanisms of resistance may limit their efficacy. Novel compounds have been recently developed to specifically target VEGF receptors, PlGF, FGF, MET, and angiopoietin. Ramucirumab, a monoclonal antibody specifically directed against the VEGFR-2, has emerged as a novel therapeutic opportunity. REGARD and RAINBOW were the first phase III studies to report the value of this strategy in gastric cancer patients, and other ongoing trials are testing novel antiangiogenic compounds. The aim of our review is to present the state-of-the-art of novel antiangiogenic compounds in advanced gastric cancer, underlying the biology, their mechanism of action, and their clinical results.

Original languageEnglish
Pages (from-to)165-178
Number of pages14
JournalCritical Reviews in Oncology/Hematology
Issue number2
Publication statusPublished - Aug 1 2015


  • Advanced gastric cancer
  • Angiogenesis
  • Bevacizumab
  • Ramucirumab

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology


Dive into the research topics of 'Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight'. Together they form a unique fingerprint.

Cite this